The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds

CompletedOBSERVATIONAL
Enrollment

131

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions
Wounds
Interventions
BIOLOGICAL

Activated allogeneic white blood cells

The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).

Trial Locations (7)

Unknown

Omer Clalit Clinic, Afula

Sold Clalit Clinic, Beersheba

Hamoshava Diabetic Wound Clinic, Jerusalem

Ramat Eshcol Wound Clinic, Jerusalem

Zvulun Wound Clinic, Kiryat Bialik

Hasharon Medical Center, Petah Tikva

Zamenhoff Wound Clinic, Tel Aviv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Macrocure Ltd.

INDUSTRY

NCT01113307 - The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds | Biotech Hunter | Biotech Hunter